Abiraterone Krka


abiraterone acetate

This medicine is authorised for use in the European Union.


Abiraterone Krka is a cancer medicine used to treat men with metastatic prostate cancer. This is cancer that affects the prostate gland (a gland of the male reproductive system). It is used when the cancer has spread to other parts of the body (metastatic).

Abiraterone Krka is used together with prednisone or prednisolone (anti-inflammatory medicines):

  • when the cancer is newly diagnosed, high risk and sensitive to hormones; Abiraterone Krka is then used in combination with a treatment called androgen deprivation therapy;
  • when medical castration (using medicines to stop the production of male hormones) with androgen deprivation therapy has not worked or no longer works in men who have either no symptoms or only mild symptoms of the disease, and who do not yet need chemotherapy (cancer medicines);
  • when medical or surgical castration and chemotherapy containing docetaxel have not worked or no longer work.

Abiraterone Krka contains the active substance abiraterone acetate and is a ‘generic medicine’. This means that Abiraterone Krka contains the same active substance and works in the same way as a ‘reference medicine’ already authorised in the EU called Zytiga.

This EPAR was last updated on 08/03/2023

Authorisation details

Product details
Abiraterone Krka
Agency product number
Active substance
abiraterone acetate
International non-proprietary name (INN) or common name
abiraterone acetate
Therapeutic area (MeSH)
Prostatic Neoplasms
Anatomical therapeutic chemical (ATC) code

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines.

Publication details
Marketing-authorisation holder
Krka, d.d., Novo mesto
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Šmarješka cesta 6
8501 Novo mesto

Product information

23/11/2022 Abiraterone Krka - EMEA/H/C/005649 - IB/0003

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Endocrine therapy

Therapeutic indication

Abiraterone Krka is indicated with prednisone or prednisolone for:

  • the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT) (see section 5.1)
  • the treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5.1)
  • the treatment of mCRPC in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.

Assessment history

How useful was this page?

Add your rating
1 rating